CompletedNot Applicable

Glucagon-like Peptide-1 Receptor Agnoists for the Assessment of Adrenal Function

Switzerland22 participantsStarted 2025-01-16

Plain-language summary

This study aims to investigate the effects of a single dose of the glucagon-like 1 receptor agonist semaglutdie/Rybelsus on the hypothalamo-pituitary-adrenal axis, thus cortisol levels and other stresshormones in healthy males.

Who can participate

Age range18 Years – 60 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Healthy male volunteers aged 18-60 years * BMI 18.5-30 kg/m2 * No regular medication Exclusion Criteria: * participation in a trial with investigational drugs within 30 days * vigorous physical exercise within 24 hours before the study participation * alcohol intake within 24 hours before the study participation * a history of intake of glucocorticoids or GLP-1 RA within the last 8 weeks. * Known allergy towards GLP-1 RA

What they're measuring

Change in serum cortisol after Rybelsus vs. Placebo

Timeframe: within 210 minutes after the intake of the study drug

Trial details

NCT IDNCT06608433

SponsorUniversity Hospital, Basel, Switzerland

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-10-31

View on ClinicalTrials.gov More Healthy Volunteer Study trials